<DOC>
	<DOCNO>NCT01570296</DOCNO>
	<brief_summary>The safety , tolerability recommend phase 2 dose ( RP2D ) combination gefitinib BKM120 determine .</brief_summary>
	<brief_title>A Trial Gefitinib Combination With BKM120 Patients With Advanced Non-Small Cell Lung Cancer , With Enrichment Patients Whose Tumours Harbour Molecular Alterations PI3K Pathway Known Overexpress EGFR</brief_title>
	<detailed_description>2.1 Primary â€¢ The safety , tolerability recommend phase 2 dose ( RP2D ) combination gefitinib BKM120 determine . 2.2 Secondary - The pharmacokinetic ( PK ) profile gefitinib combination BKM120 determine . - The preliminary anti-tumor activity gefitinib combination BKM120 determine . - The pharmacodynamic target modulation effect use hair follicle assay determine . 2.3 Exploratory - The role circulate tumour cell assess microfluidic device analyze genetic alteration implicate lung cancer , include limited EGFR mutation , PI3KCA mutation , PTEN loss characterize . - The feasibility detect somatic mutation plasma DNA ascertain .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>1 . Two patient group eligible enrolment . Either : Patients histologically cytologically proven NSCLC meet clinical definition EGFR TKI resistance , progress exist treatment previously progress EGFR TKI ( Patient Group 1 `` EGFR TKI Resistant '' ) Enrichment Cohort ( Patient Group 2 `` Pathway Driven Group '' ) Activated PI3K status ( Section 7.1 ) patient whose tumour know historically overexpress EGFR . Patients permit group standard treatment option available . 2 . Age &lt; /= 21 year 3. WHO performance status &lt; /= 2 4 . Patients must least one site measurable disease [ dose expansion phase ] ( per RECIST solid tumor appropriate disease classification/criteria target population ) 5 . Life expectancy &lt; /= 12 week 6 . Adequate bone marrow function show : ANC 1.0 x 109/L , Platelets 100 x 109/L , Hb &gt; 9 g/dL 7 . Adequate coagulation profile INR &lt; 2 8 . Total calcium ( correct serum albumin ) within normal limit ( bisphosphonate use malignant hypercalcemia control allow ) 9 . Magnesium &gt; low limit normal 10 . Alanine aminotransferase ( ALT ) aspirate aminotransferase ( AST ) within normal range ( 3.0 ULN liver metastasis present ) 11 . Serum bilirubin within normal range ( 1.5 x ULN liver metastases present ; total bilirubin 3.0 x ULN direct bilirubin within normal range patient well document Gilbert Syndrome 12 . Serum creatinine 1.5 x ULN 24hour clearance 50 mL/min 13 . Serum amylase &lt; ULN 14 . Serum lipase &lt; ULN 15 . Fasting plasma glucose &lt; 120 mg/dL ( 6.7 mmol/L ) 16 . Negative serum pregnancy test within 48 hour start study treatment woman childbearing potential 17 . Signed informed consent 1 . Patients receive prior treatment PI3K inhibitor . 2 . Patients know hypersensitivity BKM120 excipients 3 . Patients symptomatic brain metastasis exclude . However , patient metastatic CNS tumor control asymptomatic may participate trial , patient &gt; 4 week therapy completion ( incl . radiation and/or surgery ) , clinically stable time study entry receive chronic corticosteroid therapy CNS metastases 4 . Patients acute chronic liver , renal disease pancreatitis 5 . Patients follow mood disorder judge Investigator psychiatrist , result patient 's mood assessment questionnaire : i. medically document history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( immediate risk harm others ) ii . CTCAE grade 3 anxiety iii . meet cutoff score 10 PHQ9 cutoff 15 GAD7 mood scale , respectively , exclude study unless overrule psychiatric assessment . iv . selects positive response ' 1 , 2 , 3 ' question number 9 regard potential suicidal thought ideation PHQ9 ( independent total score PHQ9 ) Note : The psychiatric judgment overrules mood assessment questionnaire result/investigators judgment . 6 . Patients diarrhea &lt; CTCAE grade 2 7 . Any following concurrent severe and/or uncontrolled medical condition could compromise participation study : i. ST depression elevation &lt; 1.5 mm 2 lead ii . Congenital long QT syndrome iii . History presence ventricular arrhythmias atrial fibrillation iv . Clinically significant rest bradycardia ( &lt; 50 beat per minute ) v. QTc &gt; 480 msec screen ECG vi . Complete leave bundle branch block vii . Right bundle branch block + leave anterior hemiblock ( bifascicular block ) viii . Unstable angina pectoris &lt; 6 month prior start study drug ix . Acute myocardial infarction &lt; 6 month prior start study drug x . Other clinically significant heart disease congestive heart failure require treatment ( NYHA Class III IV ) uncontrolled hypertension ( please refer WHOISH guideline ) 8 . Patients uncontrolled diabetes mellitus steroidinduced diabetes mellitus 9 . Other concurrent severe and/or uncontrolled concomitant medical condition ( e.g. , active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol 10 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BKM120 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . Patients unresolved diarrhea exclude previously indicate 11 . Patients treat hematopoietic colonystimulating growth factor ( e.g. , GCSF , GMCSF ) 2 week prior start study drug . Erythropoietin darbepoetin therapy , initiate least 2 week prior enrollment , may continue 12 . Patients currently receive treatment medication potential prolong QT interval induce Torsades de Pointes treatment either discontinue switched different medication prior start study drug 13 . Patients receive corticosteroid 2 week prior start study drug . Topical systemic corticosteroid administer BKM120 14 . Patients receive chronic treatment steroid another immunosuppressive agent . 15 . Patients currently treat drug know moderate strong inhibitor inducer isoenzyme CYP3A , treatment discontinue switched different medication prior start study drug . Please refer Table 35 list moderate strong inhibitor CYP3A4 ( Please note cotreatment weak inhibitor CYP3A4 allow ) . 16 . Patients receive chemotherapy target anticancer therapy 4 week ( 6 week nitrosourea , antibody mitomycinC ) prior start study drug recover side effect therapy 17 . Patients receive continuous intermittent small molecule therapeutic ( exclude monoclonal antibody ) 5 effective half live prior start study drug recover side effect therapy 18 . Patients receive wide field radiotherapy 4 week limited field radiation palliation 2 week prior start study drug recover side effect therapy 19 . Patients undergone major surgery 4 week prior start study drug recover side effect therapy 20 . Patients currently take therapeutic dos warfarin sodium coumadinderivative anticoagulant . 21 . Women pregnant breast feed adult reproductive potential employ effective method birth control . Double barrier contraceptive must use trial sex . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study . Women childbearing potential , define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) , must negative serum pregnancy test &lt; 48 hour prior initiate treatment 22 . Known diagnosis human immunodeficiency virus ( HIV ) infection 23 . History another malignancy within 3 year , except cure basal cell carcinoma skin excise carcinoma situ cervix 24 . Patient unable unwilling abide study protocol cooperate fully investigator</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
	<keyword>tumor harbor molecular</keyword>
	<keyword>alteration PI3K pathway</keyword>
	<keyword>know overexpress EGFR</keyword>
</DOC>